Audit: QRS - Griffonia simplicifolia for Health & Longevity

Audit conducted on 19/08/2026 01:08 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values (100–300 mg, 100 mg, 750–900 mg), time-to-effect values, biomarker targets, gate items, benefit and risk tiers trace to ER lines 265–283, 296–309, 330, 348–366.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	marker_6_target carries the ER’s “No established target range” caveat; speculative tiers retained for both benefits and risks.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication list mirrors the ER’s own “Populations who should avoid” list (ER lines 277–283) with no severity shift; tramadol/linezolid placed as stop and dextromethorphan/methylene blue/fentanyl as caution, matching the ER’s split.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefits from Expected Benefits, risks from Potential Risks & Side Effects, gates from Key Interactions & Contraindications, protocol from Therapeutic Protocol; no modifying factors migrated into a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, author names, NCT identifiers or brand names appear anywhere in the QRS body.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, evidence-first register carried over; the ER’s British spellings (“Favourable”, “tumours”) are preserved.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and tiers paired with actionable protocol cells and the “Cheap and reversible” closing note.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as observed evidence (“the dose with the cleanest tolerability record”), not as instruction to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative or prescriptive verbs; footer disclaimer left intact.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should” or “must” in the body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Retained technical terms (Child-Pugh Class B or C, eGFR, eosinophilia-myalgia syndrome) are load-bearing decision criteria taken verbatim from the ER.
2.8	Information is presented in a concise and very compact manner	🟢	Nine ER benefit headings collapse to three tier lines; seven ER interaction bullets collapse to seven single-clause gate items with rationale stripped.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for you/your/we/our.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional biomarker ranges tighter than conventional cut-offs (ALT < 25/20 U/L, TSH 0.5–2.0 mIU/L) and a seven-item self-tracking list address this reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Three-times-daily pre-meal dosing, baseline/4-week/12-week/6-month lab cadence and a 24-hour urine collection are presented without apology.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified “just take one a day” framing; the demanding appetite regimen and its dropout rate are stated plainly.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance leads with the strongest signal (appetite) and immediately names the tolerability ceiling and the single serotonergic-combination hazard.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the header uses the ER’s canonical “for Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Body uses “gastrointestinal upset”, “adverse”, “divided doses”; the plain-language wording in at_a_glance is mandated by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings byte-identical to [qrs_template] (QRS lines 446, 490, 534, 562, 584, 613, 641, 645–647, 759).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names present; the extra names are the expanded repeatable rows marker_1–7_* and qualitative_item_1–7.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website="evidence_review", website="audit" and website="full_review" spans are untouched; a line-level diff of QRS lines 16–410 against template lines 1–407 shows only the page_title substitution.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section feeding the QRS is empty; every source section is populated.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1/2/3_label read “Standard mood protocol”, “Standard sleep protocol”, “Appetite and weight protocol”, matching ER lines 298–300 verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Biomarker names and time-to-effect labels (“Appetite and satiety”, “Mood”, “Sleep”) follow the ER’s own wording at lines 330 and 350–356.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Codepoint scan returns no symbol-category characters; the ER’s ⚠️ and tier squares are dropped, tiers conveyed by <strong> labels and CSS.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed against its ER source; gate items carry no rationale and benefit/risk tiers are single semicolon-separated lines.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Comment opens at line 2, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preamble text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no element repeats the values.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, and it contains a colon requiring YAML quoting.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: griffonia_simplicifolia_2026-0825-1111_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0819-0103.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename griffonia_simplicifolia_2026-0825-1111_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All eight keys parse cleanly; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Griffonia simplicifolia for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Griffonia simplicifolia for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/19/2026”, matching qrs_creation_date 2026-0819-0103.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block (lines 415–428) is structurally identical to the template; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Each clause maps to ER Conclusion lines 380–386: origin, strongest signal, tolerability ceiling, weaker domains, the combination hazard, cost and reversibility.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“direct building block of serotonin” (line 380), “earlier fullness … some weight lost” (382), “stomach upset drives many people to stop” (382), “modest gains in sleep and in a cognitive screening score” (382), “every serious reported harm” (384), “cheap and reversible” (386).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “cognitive screening score” rendered as “thinking-test gains”, “gastrointestinal upset” as “stomach upset”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes appear.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind appear in the at_a_glance span.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items trace to ER lines 265–283.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven bullets of the ER’s “Populations who should avoid Griffonia simplicifolia” list (lines 277–283) are represented, one-to-one.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements at QRS lines 565–579.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Rationale clauses stripped: “on absence of any safety data rather than evidence of harm” and “because of additive serotonergic effects with fentanyl and other anaesthetic agents” both removed; no dashes present.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“Child-Pugh Class B or C”, “below 30 mL/min/1.73 m²”, “within two weeks” and the “(14-day washout after stopping an MAOI)” time window (ER line 265) are all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s Key Interactions & Contraindications section uses no ranking notation.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items trace to ER lines 267–273.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The MAOI and SSRI/SNRI bullets and the tramadol/linezolid agents are excluded because they sit in [stop_items]; the remaining seven ER interaction bullets are all present.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven <li> elements at QRS lines 587–603.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Severity verdicts (“caution”, “monitor”) and mechanism sentences stripped from every bullet; no dashes present.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example lists preserved for triptans, OTC agents, serotonergic supplements and “(pyridoxine)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets use no ranking notation.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names nine interaction bullets and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol lines 298–300.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The ER’s three named dosing protocols (mood, sleep, appetite and weight) are selected over the non-actionable bullets on competing approaches, genetics and sex differences.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct actionable protocols; no set is unused.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated; values “100–300 mg daily”, “100 mg once daily”, “750–900 mg daily” and each sub-line match ER lines 298–300.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Appetite/satiety, mood and sleep are the only three domains given a time-to-effect in the ER (line 330).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Appetite and mood (both Medium tier, ER lines 139–151) precede sleep (Low tier, ER lines 153–159).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects; no set is unused.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“Within days”, “4–6 weeks” and “1–2 weeks” match ER line 330; the sub-lines derive from ER lines 212, 330 and 292.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information at line 330, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All nine ER benefit headings (lines 141–193) are represented across the three populated tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at QRS lines 536, 537, 543, 550.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Population qualifiers stripped: “in Poor Sleepers” and “in Older Adults” removed; no magnitudes or citations carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER has no High-tier benefit; benefits_high carries style="display: none" and no empty-state text (QRS line 536).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven ER risk headings (lines 210–252) are represented across the four tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at QRS lines 615, 618, 624, 630.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	“from Sustained Peripheral Serotonin Exposure” trimmed to “Valvular heart changes”; no incidence figures or case-report details carried over.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks span.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers are populated in the ER; no sub-section is empty.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table rows reproduce the ER Monitoring Protocol & Defining Success table at lines 348–356.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER biomarkers present with matching targets: eosinophil count, 24-h urinary 5-HIAA, ALT, eGFR, TSH, serum serotonin, weight and waist circumference.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS lines 750–753 carry “Baseline, then 4 weeks and 12 weeks, then every 6 months if use continues”, matching ER line 346 including the immediate-blood-count trigger.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Items reproduce the ER’s “Qualitative markers worth tracking alongside the labs” list at lines 360–366.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER qualitative markers present, in ER order, at QRS lines 761–797.

Issues 19/08/2026 01:08

Pass rate 100.00%. No issues found.